Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine-based versus standard sedation for mechanically ventilated children in paediatric intensive care
ACTRN12614000225617Phase 2Not yet recruiting
- Sponsor
- Australia and New Zealand Intensive Care Research Centre
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of dexmedetomidine in None (2 arms), sponsored by Australia and New Zealand Intensive Care Research Centre. Primary endpoint: Proportion achieving light sedation in first 48 hours. Planned start Apr 2014; status: not yet recruiting.
02
Drugs
dexmedetomidine
Beyond the preview
Go deeper on ACTRN12614000225617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000225617.